$BSX · Boston Scientific Corporation
Boston Scientific Corporation priced a registered offering of $3.0 billion aggregate principal amount of senior notes on November 19, 2026. The offering consists of four fixed-rate tranches: $1.0 billion of 5.375% notes due December 1, 2029; $750 million of 5.500% notes due December 1, 2031; $750 million of 5.750% notes due December 1, 2033; and $500 million of 5.875% notes due December 1, 2036. The notes are expected to settle on December 1, 2026, and interest will be paid semi-annually on June 1 and December 1, beginning June 1, 2027.
The company stated that it intends to use the net proceeds, together with proceeds from a concurrent euro-denominated notes offering by a subsidiary, short-term borrowings, credit agreement borrowings, and cash on hand, to finance the cash consideration for the Penumbra Acquisition and related fees and expenses. Any proceeds not used for that purpose may be applied to general corporate purposes. The notes include a special mandatory redemption feature: if the Penumbra Acquisition is not completed by the specified end date or Boston Scientific notifies the trustee that it will not pursue the acquisition, the notes must be redeemed at 101% of principal plus accrued interest.
The notes also carry make-whole call provisions prior to their respective par call dates and a change of control repurchase option at 101% of principal plus accrued interest. The joint bookrunners for the offering were BofA Securities, Citigroup, and J.P. Morgan, with several co-managers.